CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab

    NEXT STORY
    Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
    PREV STORY
    Opthea’s Phase 2b Study of OPT-302 in Wet AMD to be Presented in Late-Breaking Session of EURETINA
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference

    author_avatar
    NASDAQ Market News

    GENFIT: Major Milestone achieved with full recruitment of the Phase 2 trial evaluating elafibranor in PBC

    GENFIT: Major Milestone achieved with full recruitment of the Phase 2 trial evaluating elafibranor ...

    author_avatar
    NASDAQ Market News

    Heat Biologics Announces Closing of Public Offering

    DURHAM, N.C., March 23, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an ...

    author_avatar
    NASDAQ Market News